472 related articles for article (PubMed ID: 32411313)
1. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.
Dimopoulos G; de Mast Q; Markou N; Theodorakopoulou M; Komnos A; Mouktaroudi M; Netea MG; Spyridopoulos T; Verheggen RJ; Hoogerwerf J; Lachana A; van de Veerdonk FL; Giamarellos-Bourboulis EJ
Cell Host Microbe; 2020 Jul; 28(1):117-123.e1. PubMed ID: 32411313
[TBL] [Abstract][Full Text] [Related]
2. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.
Loscocco GG
Int J Hematol; 2020 Jul; 112(1):125-126. PubMed ID: 32474804
[No Abstract] [Full Text] [Related]
3. The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19.
Loscocco GG; Malandrino D; Barchiesi S; Berni A; Poggesi L; Guglielmelli P; Vannucchi AM
Int J Lab Hematol; 2020 Dec; 42(6):e270-e273. PubMed ID: 32776691
[No Abstract] [Full Text] [Related]
4. Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients.
Meng M; Chen L; Zhang S; Dong X; Li W; Li R; Deng Y; Wang T; Xu Y; Liu J; Huang Y; Chen Y; Huang S; Wen Z; Zhang L; Du H; Liu Y; Annane D; Qu J; Chen D
BMC Infect Dis; 2021 Apr; 21(1):398. PubMed ID: 33926377
[TBL] [Abstract][Full Text] [Related]
5. Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.
Takami A
Int J Hematol; 2020 Jul; 112(1):127. PubMed ID: 32468178
[No Abstract] [Full Text] [Related]
6. Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients.
Lorenz G; Moog P; Bachmann Q; La Rosée P; Schneider H; Schlegl M; Spinner C; Heemann U; Schmid RM; Algül H; Lahmer T; Huber W; Schmaderer C
Sci Rep; 2020 Oct; 10(1):18277. PubMed ID: 33106497
[TBL] [Abstract][Full Text] [Related]
7. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.
Takami A
Int J Hematol; 2020 Jul; 112(1):122-124. PubMed ID: 32399895
[No Abstract] [Full Text] [Related]
8. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH
J Med Case Rep; 2020 Oct; 14(1):187. PubMed ID: 33054818
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus Versus Novel Coronavirus-Induced Hemophagocytic Lymphohistocytosis: The Uncharted Waters.
Amir R; Kichloo A; Singh J; Bhanot R; Aljadah M; Kumar A; Albosta MS; Solanki S
J Investig Med High Impact Case Rep; 2020; 8():2324709620950107. PubMed ID: 32787459
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis.
Prilutskiy A; Kritselis M; Shevtsov A; Yambayev I; Vadlamudi C; Zhao Q; Kataria Y; Sarosiek SR; Lerner A; Sloan JM; Quillen K; Burks EJ
Am J Clin Pathol; 2020 Sep; 154(4):466-474. PubMed ID: 32681166
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.
González-García A; García-Sánchez I; Lopes V; Moreno-Arrones OM; Tortosa-Cabañas M; Elías-Sáenz I; Hernández-Rodríguez J
Rheumatology (Oxford); 2020 Aug; 59(8):2171-2173. PubMed ID: 32568376
[No Abstract] [Full Text] [Related]
12. Hemophagocytic lymphohistiocytosis in COVID-19: Case reports of a stepwise approach.
Schnaubelt S; Tihanyi D; Strassl R; Schmidt R; Anders S; Laggner AN; Agis H; Domanovits H
Medicine (Baltimore); 2021 Mar; 100(12):e25170. PubMed ID: 33761694
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
[No Abstract] [Full Text] [Related]
14. COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate.
Bhattacharjee S; Banerjee M; Pal R
Indian Pediatr; 2020 Sep; 57(9):827-833. PubMed ID: 32583809
[TBL] [Abstract][Full Text] [Related]
15. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
Cauchois R; Koubi M; Delarbre D; Manet C; Carvelli J; Blasco VB; Jean R; Fouche L; Bornet C; Pauly V; Mazodier K; Pestre V; Jarrot PA; Dinarello CA; Kaplanski G
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):18951-18953. PubMed ID: 32699149
[TBL] [Abstract][Full Text] [Related]
16. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
Hasselbalch HC; Poulsen A; Skov V; Kjær L; Nielsen CH; Poulsen TD
Ugeskr Laeger; 2020 Jun; 182(25):. PubMed ID: 32584762
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.
Franzetti M; Pozzetti U; Carugati M; Pandolfo A; Molteni C; Faccioli P; Castaldo G; Longoni E; Ormas V; Iemoli E; Piconi S
Int J Infect Dis; 2020 Aug; 97():215-218. PubMed ID: 32422376
[TBL] [Abstract][Full Text] [Related]
18. Use of anakinra in severe COVID-19: A case report.
Filocamo G; Mangioni D; Tagliabue P; Aliberti S; Costantino G; Minoia F; Bandera A
Int J Infect Dis; 2020 Jul; 96():607-609. PubMed ID: 32437934
[TBL] [Abstract][Full Text] [Related]
19. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?
Opoka-Winiarska V; Grywalska E; Roliński J
BMC Med; 2020 Jul; 18(1):214. PubMed ID: 32664932
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features and risk factors for secondary hemophagocytic lymphohistiocytosis in elderly patients with severe SARS-CoV-2 infection: a multicenter retrospective cohort study].
Deng Y; Lu S; Zhang G; Sun W; Chu Y; Meng M; Cui Y; Li P
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Aug; 35(8):793-799. PubMed ID: 37593855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
